INDUSTRY
Otsuka, GSK, Bayer and other execs on balancing payers, patients and physicians An integrated, multi-stakeholder approach By Paul Simms, Chairman eyeforpharma and Dr. Wolfgang Lippert, Senior Director, Healthcare and Life Sciences, SalesForce
Who is the most important stakeholder when it comes to ensuring patients gain access to new, innovative medicines? Trick question—they all are
25 | HS&M JANUARY/FEBRUARY 2019
